Biotherapeutics News and Research

RSS

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc (“Integumen”) to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert system to warn of localized COVID-19 outbreaks.

From Avacta Life Sciences Ltd. 14 Jul 2020

Single dose of flu drug can prevent influenza spread among household contacts

A single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households, new research concludes.

13 Jul 2020

World's first clinical trial of immune-boosting strategy to protect cancer patients from COVID-19

In the race to find new ways to prevent and treat COVID-19, Canadian researchers have launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations - cancer patients.

8 Jul 2020

Innovative clinical trial platform launched to accelerate testing of COVID-19 drugs

The University of Liverpool, Liverpool School of Tropical Medicine and Southampton Clinical Trials Unit announced this week that they have launched their innovative COVID-19 drug testing platform, AGILE.

8 Jul 2020

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Berkeley Lights, Inc. today announced the Opto Antigen-Presenting Bead kit, a new reagent kit that activates and expands antigen-specific T cells in blood.

From Bruker Cellular Analysis 25 Jun 2020

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Avacta Group plc is pleased to announce that the rapid test strips to detect SARS-COV-2 spike protein have been evaluated by Avacta’s partners at Cytiva.

From Cytiva Life Sciences 24 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc, is pleased to announce that collaborative work with the University of Glasgow has shown that Affimer reagents prevent infection.

From Avacta Life Sciences Ltd. 18 Jun 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

Scientists find potential new way to improve treatment for Von Willebrand Disease

Scientists have found a potential new way to promote blood clotting that could be used to help develop treatments for Von Willebrand Disease, the most common genetic bleeding disorder.

12 Jun 2020

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta Group plc is pleased to announce that a BAMS™ diagnostic test for COVID-19, being developed with Adeptrix, has reached the prototype stage.

From Avacta Life Sciences Ltd. 9 Jun 2020

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

2 Jun 2020

New Thermo Scientific Proteome Discoverer 2.5 software strengthens laboratory workflows

Scientists in the life sciences can now benefit from upgrades to a suite of analytical software solutions with new features designed to enhance productivity, confidence and accuracy in numerous fields, including proteomics, food safety and biotherapeutic drug development.

From Thermo Fisher Scientific Inc. 28 May 2020

New high-resolution mass spectrometer expands the proven Thermo Scientific Orbitrap platform

A new generation, high resolution mass spectrometer (MS) is designed to give proteomics, metabolomics, biopharmaceutical characterization and small-molecule scientists the analytical performance required for research and high-throughput analyses.

From Thermo Fisher Scientific Inc. 28 May 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

Avacta and Medusa19 enter into a distribution agreement for COVID-19 antigen test

Avacta Group plc has entered into an exclusive distribution agreement with Medusa19 Limited for sales of a saliva-based rapid test for the COVID-19 antigen.

From Avacta Life Sciences Ltd. 20 May 2020

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

Rentschler Biopharma SE, and Horizon Discovery, a leader in the application of gene editing, today announced the signing of a commercial license agreement.

From Revvity 19 May 2020

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.

From Avacta Life Sciences Ltd. 18 May 2020

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta Group plc is pleased to announce that it has entered into a collaboration with Adeptrix to develop a high throughput COVID-19 antigen test.

From Avacta Life Sciences Ltd. 1 May 2020

Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership

Avacta Group plc is pleased to announce that it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen.

From Avacta Life Sciences Ltd. 22 Apr 2020